Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bullous pemphigoid – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.

The “Bullous Pemphigoid – Pipeline Insight, 2023” report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder. It covers information about more than 5 companies and over 5 pipeline drugs related to Bullous Pemphigoid.

The report provides detailed profiles of pipeline drugs, including their clinical and nonclinical stages of development. It also assesses these therapeutics based on various factors such as product type, development stage, route of administration, and molecule type. Additionally, the report highlights any inactive pipeline products in this field.

Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Bullous Pemphigoid pipeline landscape. It includes disease background information and treatment guidelines for Bullous Pemphigoid.

The assessment section of the report delves into both commercial and clinical aspects of the pipeline products in development. It provides detailed descriptions of these drugs, including their mechanisms of action, clinical studies, NDA (New Drug Application) approvals (if any), and information about their development activities, including technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related details.

Overall, this report offers a comprehensive and detailed analysis of the Bullous Pemphigoid pipeline landscape, providing valuable insights into the current status and future prospects of potential treatments for this skin disorder.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bullous pemphigoid R&D. The therapies under development are focused on novel approaches to treat/improve Bullous pemphigoid.

Bullous pemphigoid Emerging Drugs Chapters

This segment of the Bullous pemphigoid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bullous pemphigoid Emerging Drugs

Benralizumab: AstraZeneca

Interleukin-5 (IL-5) induces an eosinophil-mediated inflammatory response by binding to the IL-5 receptor (IL-5R) expressed in eosinophils, basophils, and some mast cells. Benralizumab, unlike IL-5 low-affinity binding, binds with high affinity to the domain I of the a-chain of IL-5R and blocks its signaling and the proliferation of IL-5-dependent cell lines.

On the other hand, Benralizumab is an afucosylated antibody in the CH2 region which gives it a high affinity for the Fc-g RIIIa  on natural killer cells, macrophages, and neutrophils. This binding triggers a magnified apoptosis response in eosinophils via antibody-dependent cell-mediated cytotoxicity. Currently, it is in the Phase III stage of clinical trial evaluation to treat Bullous Pemphigoid.

Dupilumab: Regeneron/Sanofi

Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor a (IL-4Ra) that inhibits both IL-4 and IL-13 signaling. Dupilumab (Dupixent) is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP.

The drug is in Phase III clinical studies for Bullous Pemphigoid. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. Dupilumab was invented using Regeneron’s proprietary VelocImmune technology. The FDA has granted orphan drug designation to dupilumab for the treatment of Bullous Pemphigoid.

Bullous pemphigoid: Therapeutic Assessment

This segment of the report provides insights about the different Bullous pemphigoid drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bullous pemphigoid

• There are approx. 6+ key companies which are developing the therapies for Bullous pemphigoid. The companies which have their Bullous pemphigoid drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bullous pemphigoid drugs?
• How many Bullous pemphigoid drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bullous pemphigoid?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bullous pemphigoid therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bullous pemphigoid and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Sanofi
• Innate Pharma

Key Products

• Benralizumab
• Dupilumab
• Avdoralimab

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Bullous pemphigoid Report Insights

• Bullous pemphigoid Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bullous pemphigoid Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/tqlwa0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900